Visium Asset Management’s Albany Molecular Research Inc AMRI Stock Holding History

Visium Asset Management’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-2,009,452	Closed	-$30.7M	–	570
2016 Q1	$30.7M	Sell	2,009,452 -89,348	-4%	-$1.4M	0.52%	42
2015 Q4	$41.7M	Sell	2,098,800 -1,201,200	-36%	-$22.8M	0.63%	29
2015 Q3	$57.5M	Buy	3,300,000 +100,000	+3%	+$2.04M	0.79%	22
2015 Q2	$64.7M	Buy	3,200,000 +1,820,000	+132%	+$35.1M	0.92%	15
2015 Q1	$24.3M	Sell	1,380,000 -1,820,000	-57%	-$31M	0.36%	55
2014 Q4	$52.1M	Buy	3,200,000 +2,000,000	+167%	+$36.7M	0.74%	24
2014 Q3	$26.5M	Sell	1,200,000 -970,000	-45%	-$19.9M	0.39%	46
2014 Q2	$43.7M	Sell	2,170,000 -980,000	-31%	-$16.6M	0.68%	18
2014 Q1	$58.6M	Hold	3,150,000	–	–	0.95%	14
2013 Q4	$31.8M	Buy	3,150,000 +1,115,000	+55%	+$13.5M	0.62%	28
2013 Q3	$26.2M	Buy	+2,035,000	New	+$25M	0.59%	34

Other funds holding AMRI

PIP

Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

OWP

Obermeyer Wealth Partners Aspen, Colorado $2.44B AUM 24.34% 1-Year Est. Return

VNIM

Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Visium Asset Management's AMRI Position: Q2 2016 in Review

Visium Asset Management sold out of Albany Molecular Research Inc (AMRI) in Q2 2016, closing a stake of 2,009,452 shares — an estimated $30.7M sold.

Visium Asset Management first reported a position in AMRI in Q3 2013 and held it in 11 quarters. The position peaked at $64.7M in Q2 2015. 142 funds tracked by Wall St. Rank hold AMRI as of Q2 2016.

Visium Asset Management reported no remaining Albany Molecular Research Inc position as of Q2 2016 after selling out during the quarter.
Visium Asset Management sold 2,009,452 Albany Molecular Research Inc shares in Q2 2016, an estimated $30.7M.
Visium Asset Management first reported a position in Albany Molecular Research Inc in Q3 2013 and held it in 11 quarters.
Visium Asset Management's Albany Molecular Research Inc position peaked at $64.7M in Q2 2015.
142 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.